Clinical Trial now recruiting for Secondary Progressive MS
Clozapine and risperidone are currently used to treat mental illnesses but have been shown to have anti-inflammatory effects in the brain and therefore may also be useful for treating MS.
The study is being run in Wellington and is currently looking for participants who:
For more information see here
We want you to help inform us about what the needs are within the MS Community in NZ and how we can work and advocate to help improve services.
See here for more information
Take the survey today https://www.surveymonkey.com/r/NZMSCARESURVEY
MSNZ welcomes PHARMAC’s decision to fund two new first-line treatments for relapsing- remitting forms of Multiple Sclerosis.
The Multiple Sclerosis Society of New Zealand (MSNZ) welcomes PHARMAC’s decision to fund two new first-line treatments for relapsing-remitting forms of MS.
The new treatments: dimethyl fumarate (Tecfidera) supplied by Biogen NZ and teriflunomide (Aubagio) supplied by Sanofi-Aventis NZ will be funded in the community and in DHB hospitals, subject to the same restrictions that apply to natalizumab (Tysabri) and fingolimod (Gilenya).
Click Here for more information
If you would like further information and support you can contact your Regional Society directly. All our Regional Socieites employ skilled and experienced Field Workers who are available to you and your family and carers to provide on-going support, information and advice.
Contact your nearest regional MS Society
Multiple Sclerosis New Zealand
The Multiple Sclerosis Society of New Zealand (Inc) is a non-profit organisation formed to provide on-going support, education and advocacy for people with MS and their support networks. It also aims to educate the general public, employers and health professionals about MS and actively funds key research into the condition. The Society was formed in 1967 and today there are 18 Regional Societies from Northland to Southland supported through advice, education and materials by the National Office.